Jianping Jia, MD, PhD, Professor of Neurology, Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Changchun Street 45, Xicheng District, Beijing, China, 100053, Tel: +86-10-83199449, e-mail:
J Prev Alzheimers Dis. 2024;11(3):701-709. doi: 10.14283/jpad.2024.29.
The polygenic risk score (PRS) aggregates the effects of numerous genetic variants associated with a condition across the human genome and may help to predict late-onset Alzheimer's disease (LOAD). Most of the current PRS studies on Alzheimer's disease (AD) have been conducted in Caucasian ancestry populations, while it is less studied in Chinese.
To establish and examine the validity of Chinese PRS, and explore its racial heterogeneity.
We constructed a PRS using both discovery (N = 2012) and independent validation samples (N = 1008) from Chinese population. The associations between PRS and age at onset of LOAD or cerebrospinal fluid (CSF) biomarkers were assessed. We also replicated the PRS in an independent replication cohort with CSF data and constructed an alternative PRS using European weights.
Multi-center genetics study.
A total of 3020 subjects were included in the study.
PRS was calculated using genome-wide association studies data and evaluated the performance alone (PRSnoAPOE) and with other predictors (full model: LOAD ~ PRSnoAPOE + APOE+ sex + age) by measuring the area under the receiver operating curve (AUC).
PRS of the full model achieved the highest AUC of 84.0% (95% CI = 81.4-86.5) with pT< 0.5, compared with the model containing APOE alone (61.0%). The AUC of PRS with pT<5e-8 was 77.8% in the PRSnoAPOE model, 81.5% in the full model, and only ranged from 67.5% to 75.1% in the PRS with the European weights model. A higher PRS was significantly associated with an earlier age at onset (P <0.001). The PRS also performed well in the replication cohort of the full model (AUC=83.1%, 95% CI = 74.3-92.0). The CSF biomarkers of Aβ42 and the ratio of Aβ42/Aβ40 were significantly inversely associated with the PRS, while p-Tau181 showed a positive association.
This finding suggests that PRS reveal genetic heterogeneity and higher prediction accuracy of the PRS for AD can be achieved using a base dataset and validation within the same ethnicity. The effective PRS model has the clinical potential to predict individuals at risk of developing LOAD at a given age and with abnormal levels of CSF biomarkers in the Chinese population.
多基因风险评分(PRS)聚合了与人类基因组中某种疾病相关的大量遗传变异的影响,可帮助预测迟发性阿尔茨海默病(LOAD)。大多数关于阿尔茨海默病(AD)的当前 PRS 研究都是在白种人血统人群中进行的,而在中国研究较少。
建立并检验中国 PRS 的有效性,并探讨其种族异质性。
我们使用来自中国人群的发现(N=2012)和独立验证样本(N=1008)构建了 PRS。评估 PRS 与 LOAD 的发病年龄或脑脊液(CSF)生物标志物之间的关联。我们还在具有 CSF 数据的独立复制队列中复制了 PRS,并使用欧洲权重构建了替代 PRS。
多中心遗传学研究。
共有 3020 名受试者纳入研究。
使用全基因组关联研究数据计算 PRS,并单独评估(PRSnoAPOE)和与其他预测因子(全模型:LOAD~PRSnoAPOE+APOE+性别+年龄)的表现,通过测量接收器工作曲线下的面积(AUC)。
全模型的 PRS 达到了最高 AUC 为 84.0%(95%CI=81.4-86.5),pT<0.5,与仅包含 APOE 的模型(61.0%)相比。在 PRSnoAPOE 模型中,pT<5e-8 的 PRS 的 AUC 为 77.8%,在全模型中为 81.5%,而在使用欧洲权重模型中仅为 67.5%至 75.1%。较高的 PRS 与发病年龄较早显著相关(P<0.001)。PRS 在全模型的复制队列中表现良好(AUC=83.1%,95%CI=74.3-92.0)。CSF 生物标志物 Aβ42 和 Aβ42/Aβ40 的比值与 PRS 呈显著负相关,而 p-Tau181 呈正相关。
这一发现表明 PRS 揭示了遗传异质性,并且在同一族群中使用基础数据集和验证可以实现 AD 的 PRS 更高的预测准确性。有效的 PRS 模型具有预测给定年龄个体发生 LOAD 的风险和中国人群中 CSF 生物标志物异常水平的临床潜力。